182 related articles for article (PubMed ID: 33108799)
21. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
[TBL] [Abstract][Full Text] [Related]
22. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
[TBL] [Abstract][Full Text] [Related]
23. Rituximab for rapidly progressive juvenile systemic sclerosis.
Zulian F; Dal Pozzolo R; Meneghel A; Castaldi B; Marcolongo R; Caforio ALP; Martini G
Rheumatology (Oxford); 2020 Dec; 59(12):3793-3797. PubMed ID: 32442284
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort.
Kuster S; Jordan S; Elhai M; Held U; Steigmiller K; Bruni C; Cacciapaglia F; Vettori S; Siegert E; Rednic S; Codullo V; Airo P; Braun-Moscovici Y; Hunzelmann N; Joao Salvador M; Riccieri V; Gheorghiu AM; Alegre Sancho JJ; Romanowska-Prochnicka K; Castellví I; Kötter I; Truchetet ME; López-Longo FJ; Novikov PI; Giollo A; Shirai Y; Belloli L; Zanatta E; Hachulla E; Smith V; Denton C; Ionescu RM; Schmeiser T; Distler JHW; Gabrielli A; Hoffmann-Vold AM; Kuwana M; Allanore Y; Distler O;
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328401
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Kondo N; Fujisawa J; Endo N
Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
Sakkas LI
Drug Des Devel Ther; 2016; 10():2723-8. PubMed ID: 27621593
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
28. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
[TBL] [Abstract][Full Text] [Related]
30. TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.
Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Sainz de la Maza M; Adán A
Retina; 2018 Jul; 38(7):1361-1370. PubMed ID: 28520640
[TBL] [Abstract][Full Text] [Related]
31. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
[TBL] [Abstract][Full Text] [Related]
32. Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?
Martini G; Campus S; Raffeiner B; Boscarol G; Meneghel A; Zulian F
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):211-213. PubMed ID: 28980909
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of children with juvenile systemic sclerosis using mycophenolate mofetil after methylprednisolone pulse therapy: A 3-year follow-up.
Furusawa A; Wakiguchi H; Okazaki F; Korenaga Y; Azuma Y; Yasudo H; Hasegawa S
Int J Rheum Dis; 2022 Jan; 25(1):95-96. PubMed ID: 34866347
[No Abstract] [Full Text] [Related]
34. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.
Ortiz-Sanjuán F; Blanco R; Calvo-Rio V; Narvaez J; Rubio Romero E; Olivé A; Castañeda S; Gallego Flores A; Hernández MV; Mata C; Ros Vilamajo I; Sifuentes Giraldo WA; Caracuel MA; Freire M; Gómez Arango C; Llobet J; Manrique Arija S; Marras C; Moll-Tuduri C; Plasencia-Rodriguez C; Roselló R; Urruticoechea A; Velloso-Feijoo ML; Del Blanco J; González-Vela MC; Rueda-Gotor J; Pina T; Loricera J; González-Gay MA
Arthritis Rheumatol; 2014 Jun; 66(6):1659-65. PubMed ID: 24515813
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.
Cañas CA; Cañas F; Izquierdo JH; Echeverri AF; Mejía M; Bonilla-Abadía F; Tobón GJ
J Clin Rheumatol; 2014 Apr; 20(3):125-9. PubMed ID: 24662551
[TBL] [Abstract][Full Text] [Related]
37. Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment.
Kostik MM; Isupova EA; Chikova IA; Dubko MF; Masalova VV; Snegireva LS; Kalashnikova OV; Chasnyk VG
Clin Exp Rheumatol; 2018; 36(2):335-341. PubMed ID: 29303703
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
39. Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A; Walker KM; Pope JE;
Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
[TBL] [Abstract][Full Text] [Related]
40. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
